ID Source | ID |
---|---|
PubMed CID | 11909 |
CHEMBL ID | 3184586 |
SCHEMBL ID | 836649 |
MeSH ID | M0108342 |
Synonym |
---|
1-methyl-2-nitroso-benzene |
ccris 480 |
brn 1927295 |
nsc 66507 |
2-methylnitrosobenzene |
einecs 210-261-4 |
nsc677512 |
nsc-677512 |
o-nitrosotoluene |
nsc66507 |
1-methyl-2-nitrosobenzene |
toluene, o-nitroso- |
611-23-4 |
o-methylnitrosobenzene |
2-methyl-1-nitrosobenzene |
2-nitrosotoluene |
benzene, 1-methyl-2-nitroso- |
nsc-66507 |
2-nitrosotoluene, 97% |
NCGC00248875-01 |
tox21_200917 |
NCGC00258471-01 |
cas-611-23-4 |
dtxsid3021065 , |
dtxcid901065 |
4-05-00-00844 (beilstein handbook reference) |
unii-h2p2o30zss |
h2p2o30zss , |
AKOS015889069 |
SCHEMBL836649 |
1‐methyl‐2‐nitrosobenzene (substrate 3) |
bdbm108226 |
ortho-nitrosotoluene |
nitrosotoluene |
CHEMBL3184586 |
Q27279561 |
AS-83108 |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 6.2688 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521 |
AR protein | Homo sapiens (human) | Potency | 63.2472 | 0.0002 | 21.2231 | 8,912.5098 | AID743035 |
nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 55.8707 | 0.0010 | 22.6508 | 76.6163 | AID1224838 |
nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 23.5605 | 0.0006 | 27.2152 | 1,122.0200 | AID743219 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Process | via Protein(s) | Taxonomy |
---|---|---|
magnesium ion binding | 1-deoxy-D-xylulose-5-phosphate synthase | Escherichia coli K-12 |
1-deoxy-D-xylulose-5-phosphate synthase activity | 1-deoxy-D-xylulose-5-phosphate synthase | Escherichia coli K-12 |
transferase activity | 1-deoxy-D-xylulose-5-phosphate synthase | Escherichia coli K-12 |
transketolase or transaldolase activity | 1-deoxy-D-xylulose-5-phosphate synthase | Escherichia coli K-12 |
thiamine pyrophosphate binding | 1-deoxy-D-xylulose-5-phosphate synthase | Escherichia coli K-12 |
protein homodimerization activity | 1-deoxy-D-xylulose-5-phosphate synthase | Escherichia coli K-12 |
metal ion binding | 1-deoxy-D-xylulose-5-phosphate synthase | Escherichia coli K-12 |
[Information is prepared from geneontology information from the June-17-2024 release] |
Process | via Protein(s) | Taxonomy |
---|---|---|
cytosol | 1-deoxy-D-xylulose-5-phosphate synthase | Escherichia coli K-12 |
cytosol | 1-deoxy-D-xylulose-5-phosphate synthase | Escherichia coli K-12 |
[Information is prepared from geneontology information from the June-17-2024 release] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1800220 | DXP Synthase Inhibition Assay from Article 10.1002/cbic.201300187: \\DXP synthase-catalyzed C-N bond formation: nitroso substrate specificity studies guide selective inhibitor design.\\ | 2013 | Chembiochem : a European journal of chemical biology, Jul-22, Volume: 14, Issue:11 | DXP synthase-catalyzed C-N bond formation: nitroso substrate specificity studies guide selective inhibitor design. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 2 (40.00) | 18.7374 |
1990's | 1 (20.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 1 (20.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.47) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |